June 2008

Serum Uric Acid and Clinical Progression in Parkinson DiseasePotential Biomarker for Nigrostriatal Failure

Author Affiliations

Copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2008

Arch Neurol. 2008;65(6):698-699. doi:10.1001/archneur.65.6.698

Parkinson disease (PD) is the second most common neurodegenerative disorder, with a prevalence and incidence rate that increases significantly with age. In North America, an estimated 1% of the population older than 65 years has PD. During the past decade, our understanding of this disease has been radically transformed, particularly regarding its neuropathology, molecular biology, and genetics. Nonetheless, PD remains clinically defined, using the comprehensive neurological examination as the gold standard and clinical measures such as the Unified Parkinson Disease Rating Scale (UPDRS) and the Hoehn & Yahr (H&Y) disability staging to confirm diagnosis and to assess disease progression.1,2

First Page Preview View Large
First page PDF preview
First page PDF preview